Granalix

Granalix GranaGard is a product of Granalix Bio Technologies LTD. Granalix is a startup biotechnology company

Post your answers below...
16/10/2019

Post your answers below...

06/06/2018

granalix.com at Vitafoods Europe

Busy at   at booth P153                            Vitafoods Europe
17/05/2018

Busy at at booth P153

Vitafoods Europe

  at   booth P153       Vitafoods Europe
17/05/2018

at booth P153

Vitafoods Europe

17/05/2018

Excited to start Day 3 at Vitafoods Europe

Visit at booth P153

 , a   based on   used to prevent  . Visit us at   booth P153   Vitafoods Europe
17/05/2018

, a based on used to prevent .

Visit us at booth P153

Vitafoods Europe

Emmanuel Fiessinger from www.seventure.fr  visited   and was interested in hearing about  . Seventure has invested in   ...
16/05/2018

Emmanuel Fiessinger from www.seventure.fr visited and was interested in hearing about .

Seventure has invested in DayTwo

All this at booth P153

16/05/2018

Busy here at booth P153
Vitafoods Europe

  with Theo Smits from TS Products at   Vitafoods Europe
16/05/2018

with Theo Smits from TS Products at

Vitafoods Europe

Address

Jerusalem

Alerts

Be the first to know and let us send you an email when Granalix posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Granalix:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Team

Granalix is a startup biotechnology company founded by Prof Ruth Gabizon from the Neurology Department of the Hadassah Medical Center and Prof Shlomo Magdassi, from the Casali Institute of Chemistry of The Hebrew University.

Granagard is the results of their combined experience and knowledge. The company was founded under the umbrella of Hadasit and Yissum, the technology transfer companies of Hadassah Medical Center and the Hebrew University of Jerusalem.